idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
idw - Informationsdienst
Wissenschaft
Coldplasmatech, a spin-off in the field of medical cold plasma technology from the Leibniz Institute for Plasma Science and Technology in Greifswald and winner of the 2015 Leibniz Start-Up Prize, has entered into a strategic partnership with Royal Biologics, a private equity-backed leader in orthobiologic and advanced wound care solutions. With Royal Biologics strong financial investment, this collaboration enables the international footprint expansion of Coldplasmatech’s innovative Cold Atmospheric Plasma (CAP) technology, setting a new standard in the treatment of complex and chronic wounds.
Chronic and acute wounds affect nearly one billion people globally and contribute to an estimated $50 billion in annual healthcare costs in the United States alone. Addressing this urgent medical challenge, Coldplasmatech’s Cold Atmospheric Plasma (CAP) technology, which includes the CPT®cube and CPT®patch, delivers an effective, rapid, and safe therapy for chronic wounds. It is registered in the European Union as a Class IIb medical device.
Salvatore Leo, CEO and founder of Royal Biologics and its wound care division, Royal Wound-X, stated “We are investing not only in the future of wound care but also in plasma medicine, which is evolving from handheld devices to automated full-body treatments, taking this technology to a new level. Coldplasmatech sets itself apart with its fully automated system and the ability to treat large wound areas independently of depth.” said Leo. “This marks a paradigm shift in chronic wound care and antimicrobial resistance. Our partnership will redefine treatment approaches and improve patient outcomes worldwide.”
“Chronic wounds and antimicrobial resistance are among the greatest challenges in modern medicine, yet treatment options have remained largely unchanged for decades,” said Dr. Carsten Mahrenholz, CEO of Coldplasmatech GmbH. “Our groundbreaking technology introduces an entirely new approach, one that actively supports wound healing while directly combating multi-drug-resistant bacteria. With Royal Biologics' extensive market reach and commitment to innovation, this partnership paves the way for global adoption of a long-overdue shift in wound care.”
The partnership was strategically supported by consultants GR Consulting and Dentons, with additional support from the Innovation Alliance of the European Wound Management Association (EWMA). The EWMA is a European non-profit umbrella organisation that connects national wound management organisations, individuals and groups with an interest in wound care and promotes evidence-based medicine.
“The collaboration between Coldplasmatech and Royal Biologics is a crucial step forward in advancing innovative wound care solutions that benefit both patients
and healthcare systems.” said Dr. Edwin den Braber from EWMA Innovation Alliance.
Innovative Technology for Advanced Wound Healing
Coldplasmatech’s patented CPT® system is inspired by science fiction’s dermal regenerators and utilizes ionized gas to create a bioactive healing environment. The plasma effect reduces bacterial burden, including antibiotic-resistant pathogens, and enhances cellular regeneration. With a simple two-minute application, the therapy integrates seamlessly into standard clinical workflows and can be combined with other advanced treatments, such as negative pressure therapy and skin substitute matrices.
The technology is already in use at leading medical institutions, including Hannover Medical School and University Heart Center Hamburg. Prof. Dr. Markus Barten from the University Heart Center Hamburg summarizes: “The simple handling allows for quick and painless wound care with high effectiveness, to the delight of patients.”
Press contact:
COLDPLASMATECH GmbH
Finn Manthe
Bahnhofstrasse 31
17489 Greifswald
Telefon: +49 170 3028 345
E-Mail: manthe@coldplasmatech.de
About Coldplasmatech GmbH
Founded in 2015 as a spin-off of the Leibniz Institute for Plasma Science and Technology, Coldplasmatech GmbH is based in Greifswald, Germany. The company has received international recognition for its CPT® cold plasma therapy, earning prestigious awards such as the German Innovation Award, Bavarian Innovation Award, and IQ Innovation Award.
Coldplasmatech is currently conducting the POWER study, the world's largest ongoing randomized controlled trial on chronic, non-healing lower leg wounds. This study is supported by the German Federal Ministry of Education and Research.
For further information: http://www.coldplasmatech.com and http://www.powerstudie.com
About Royal Biologics
Founded in 2015 and headquartered in Hackensack, NJ, Royal Biologics specializes in the development, licensing, production, and distribution of orthobiologic and wound care products. Their portfolio includes autologous biologics, cellular bone grafts, advanced synthetics, and specialized wound care solutions. With backing from private equity firm Granite Creek Capital Partners, Royal Biologics continues to drive innovation in regenerative medicine and orthopedic surgery.
For further information: http://www.royalbiologics.com
Example of wound treatment by a wound expert from the Plasma Competence Centre MeckCura using the CP ...
Source: Coldplasmatech Gmbh
Criteria of this press release:
Business and commerce, Journalists
Medicine, Nutrition / healthcare / nursing, Physics / astronomy
transregional, national
Transfer of Science or Research
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
